We reasoned that the KSL-128114 inhibitor could potentially be used to affect syntenin’s role in receptor trafficking, as well as potential interactions between syntenin and the SARS-CoV-2 proteins, which could affect viral infection. The gene discussed is SDCBP; the disease is viral infectious disease.